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DNA microarrays provide a versatile platform for applications including gene expression analysis and genotyping. In the case of cystic
fibrosis (CF), DNA microarrays enable the measurement of gene expression levels of thousands of genes in parallel, and potentially therefore,
to identify non-CFTR genes down- or up-regulated in CF, which could lead to insights into disease pathophysiology, as well as novel
molecular markers and therapeutic strategies. Moreover, using optimised microarray protocols based on either primer extension analysis (i.e.
minisequencing) or electronic hybridisation stringency control, the potential now exists to detect all relevant CFTR mutations on a single
DNA microarray as a novel platform for CF screening.
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Following the completion of the first draft of the human
genome sequence [1], it is now possible to design probes
specific for all target genes relevant to any given investiga-
tion. High-density arrays (microarrays) of either oligonu-
cleotide or complementary DNA (cDNA) probes for these
genes provide the basis for highly parallel analysis of DNA
sequences. Although DNA microarrays are already being
applied to several areas of biology, they are becoming
particularly indispensable in biomedical research for gene
expression profiling [2] (i.e. measurement of variation in
expression of a large number of genes under differing
physiological or pathological circumstances) and large-scale
genotyping [3] (i.e. variation in gene sequences within and
between populations).
In cystic fibrosis (CF), more than 1200 mutations have
been identified to date in the CFTR gene [4]. While many of
these mutations are extremely rare and not all mutations are
disease-causing, there is a clear need for a novel platform
for genetic testing of CF which can provide simultaneous
screening of a large proportion of CFTR mutations with a1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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which would be compatible with a high throughput screen-
ing programme [5]. DNA microarray platforms have been
developed using different approaches to implement muta-
tion detection [3,6,7], and thus the potential exists for such
platforms to provide a complete solution to CFTR mutation
detection for CF screening.
However, the classification of clinical CFTR-associated
syndromes cannot be based entirely on CFTR mutations [8].
Genotype–phenotype correlations are not always consistent
as was evident from a study of patients homozygous for
F508del (the most common CFTR mutation) [9], where
both the nature of the clinical phenotype and the severity of
the symptoms differed even within siblings. Many studies
now clearly suggest that other genes (together with envi-
ronmental factors) contribute to the severity of CF clinical
symptoms. DNA microarrays have been developed for gene
expression analysis that can simultaneously measure the
relative expression of thousands of genes, and initial studies
using this approach [10,11] have already provided evidence
of changes in the level of expression of other genes due to
CFTR deficiency.
This article will therefore explore the opportunities to
provide a novel screening platform for CF using DNA
microarrays designed for mutation detection, as well as to
increase the knowledge of the pathogenesis of CF usinged by Elsevier B.V. All rights reserved.
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profiling.2. Background on DNA microarrays
Microarrays exploit the ability of short oligonucleotide
(i.e. synthetic single stranded DNA 20–60 bp long) or longer
cDNA probes immobilised on a functionalised solid support
substrate (e.g. glass) to hybridise and capture a complemen-
tary sequence on a target sample of RNA or DNA. While
DNA microarrays are typically based on the standard mi-
croscope slide format (i.e. glass 25 75 mm), alternative
substrates based on gold, silicon, metal oxides and polymers
are becoming more commonly used due to favourable
optical, chemical or structural properties [12]. Currently,
DNA microarrays are manufactured either by in situ synthe-
sis of short oligonucleotides [13,14], or by robotic deposition
(i.e. spotting) of presynthesised oligonucleotides [15]. In situ
synthesis of DNA microarrays is based on the combination
of state-of-the-art photolithographic techniques with phos-
phoramidite chemistry to generate an array of oligonucleo-
tide probes where each probe occupies as little as 10 10
Am. The major advantage of this approach is that hundreds of
thousands of probes can be arrayed in a single microarray,
e.g. GenechipR arrays (Affymetrix, Santa Clara, US) have
over 500,000 probe locations, or features, within a mere 1.28
cm2. Limitations of this manufacturing technique are that it is
not feasible to synthesise probes longer than 25 bp due to
synthesis errors, and the set-up cost of manufacture is very
high, making low volume production prohibitively expen-
sive [16]. An alternative approach for in situ synthesis has
recently been developed which overcomes these limitations
through the combined use of an ink-jet printing process in
combination with phosphoramidite chemistry [17] (i.e. Agi-
lent SurePrintk technology).
The more commonly used approach to microarrray
manufacture involves robotic deposition of the presynthe-
sised oligonucleotides or cDNA on a functionalised, i.e.
chemically activated, surface by means of a robotic spotter
[15]. The spotter consists of a high-precision X–Y–Z-stage
(e.g. accurate to 5 Am) with a robotic arm connected either
to a pin or a miniature pipette, where microlitre quantities of
each DNA probe are initially collected from a microwell
plate and then nanolitre quantities of those probes are
sequentially dispensed in an array format on to tens of
functionalised slides. This approach affords the flexibility to
deposit either cDNA or purified oligonucleotides in a
customised configuration, and it is ideal for low volume
production of arrays typical of research laboratories. A
major limitation in the uptake of this technology has been
the cost of the equipment and the need for experienced
operators to ensure a high degree of reproducibility within
and between microarrays [18].
An alternative approach for manufacturing DNA micro-
arrays involves the use of an electronically addressablemicroarray platform [7] (i.e. NanoChipR from Nanogen,
San Diego, US) where the DNA probes are introduced one
at a time, and localised using electric fields. The main
limitations of this microarray platform are the relatively
low number of electronically addressable sites for DNA
probe attachment, together with the relatively high costs of
the chips and control system combined. However, the ability
to transport, localise and concentrate DNA on-chip affords
capabilities for microarray analysis on this platform that are
not possible using inert substrates, and which are discussed
below.
All microarray platforms rely on the unique molecular
recognition characteristic of the hybridisation of a target
strand of DNA/RNA to an immobilised probe. However,
there are a variety of different approaches for implementa-
tion of target DNA hybridisation and detection depending
on the level of sequence homology between match and mis-
match probes, and the visualisation platform being utilised.
These approaches will now be reviewed in the context of
DNA microarray applications to mutation detection in the
CFTR gene and analysis of gene expression associated with
CF over the whole genome.3. Microarray-based gene expression analysis in CF
Gene expression profiling is probably the most widely
used research application of DNA microarrays so far, and
may be defined as the collection of relative mRNA expres-
sion values for hundreds or thousands of different genes at
one time point or condition [3]. Performing microarray gene
expression profiling is thus to assess in a sample of interest
(e.g. disease-affected tissue or cell line) the abundance of
each mRNA species (resulting from the transcriptional
activity/expression level of a particular gene) for which
there is a probe (or more than one probe) spotted on the
array. As the activity of a large number of genes is assayed
by a one-step procedure, the experiment itself may be easily
applied to large numbers of individuals, making the cost of
each experiment the only limiting step. Typically, gene
expression analysis involves isolation of mRNA from both
test (e.g. sample of tissue from CF patient) and control
samples, labelling of both mRNAs (e.g. with different
fluorescent dyes), performing hybridisation on a microarray
so that the level of hybridisation to any specific probe is
proportional to the abundance of mRNA complementary to
that probe. Using a microarray scanner, the intensity of
fluorescence at each location can be quantified, thus en-
abling the level of gene expression to be compared between
the test and control samples. Analysis of the data, which
includes expression values from the experimental sample
and a well-matched control, will reveal which genes are up-
or down-regulated in the sample of interest. To be informa-
tive, signals detected in the gene profiling arrays should be
measurable on a continuous scale (not just ‘on’ or ‘off’), as
genes overexpressed by 20-fold are more likely to have a
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disease) than those undergoing just a 1.5-fold increase in
expression. Differences < 2-fold are usually ignored be-
cause they are considered to be within the variability range
of the experiments (even after repeated experiments and
statistical analysis). In any case, if one wants to re-evaluate a
gene of particular interest, differences determined by micro-
array experiments should be confirmed by an independent
method (e.g. Northern blot).
An example of a microarray gene expression study can
already be found in the field of CF research as reported by
Xu et al. [10]. In this case, microarray analyses of lung
mRNA expression were performed using tissue from mice
lacking (i.e. CFTR knockout) or expressing the mouse
wtCFTR gene. Statistically significant increases in 29 and
decreases in 25 of the approximately 12,500 mouse genes
represented on the chosen array were observed in the CFTR
knockout samples. Genes with expression levels that were
consistently altered by the absence of CFTR were found to
be associated with several functional classes of proteins,
including those involved in gene transcription, inflamma-
tion, intracellular trafficking, signal transduction and ion
transport. This information led to speculation about how the
regulated genes might contribute to diverse pulmonary cell
functions to ameliorate or contribute to CF pathogenesis,
equivalent to a cascade effect compensating for the absence
of a functional CFTR protein. It is important to stress,
however, that such data are merely a basis from which to
form new functional hypotheses about individual genes,
proteins and pathways which must then be tested or vali-
dated using conventional experimental methods. However,
based on multiple samples obtained from cancer patients,
Golub et al. [19] reported that predictions based on gene
expression levels of 50 genes (out of an initial 6000
screened on the array) enabled highly accurate classification
of the tumours. Noguchi et al. [20] developed a novel
microarray encompassing some 3500 genes specifically
expressed in skeletal muscle. The array was then used to
analyse gene expression in muscle samples from individual
patients suffering from Duchenne muscular dystrophy. In-
dividual differences in the expression of genes encoding
HLA-related proteins, myosin light chains and troponin Ts,
markers of muscle necrosis and regeneration, were found,
and these data were highly relevant to pathophysiological
alterations in each patient. In this case, a refinement of the
gene expression analysis method was thus used to create a
microarray tool geared towards one specific disease, and a
similar scenario can be envisaged in the near future for a
variety of other genetic diseases including CF.4. Microarray-based CFTR mutation detection
To date, over 1200 mutations in the CFTR gene have been
reported [4]. While most of the mutations are extremely rare
and only a proportion leads to a defective CFTR protein (i.e.resulting in CF), it is generally accepted that there is a need
for a novel genetic analysis platform for CF testing.
Dequeker et al. [21] provide a review of existing genetic
testing methods for CF, including heteroduplex analysis,
restriction enzyme analysis, Amplification Refractory Mu-
tation System (ARMS), oligonucleotide ligation assay
(OLA), single stranded conformational polymorphism
(SSCP) and direct sequencing. Only the latter is capable of
identifying all mutations, but is not feasible for routine
screening. Therefore, routine testing for CFTR mutations
in most diagnostics labs is limited to a small number of the
most frequent mutations, such as the 25 mutations recom-
mended by the American College of Obstetricians and
Gynecologists (ACOG) and the American College of Med-
ical Genetics (ACMG) [22,23]. However, in a worldwide
analysis of the distribution of CFTR mutations, Bobadila et
al. [4] report a substantial variation in CFTR mutations
across different geographic regions, and highlight the limi-
tations in testing sensitivity associated with the use of only a
limited ‘‘pan-ethnic’’ panel of 25 mutations. Given the
relatively high prevalence of CF, and the fact that early
diagnosis facilitates timely initiation of treatment pro-
grammes, national post-natal screening programmes are
being considered in many countries, which will necessitate
high-throughput (and preferable low-cost) screening of
CFTR mutations. Therefore, key challenges for an optimised
CFTR mutation detection platform are:
(a) It should deliver a very high level of accuracy,
(b) It must be capable of simultaneous analysis of a large
proportion of CFTR mutations across several different
populations,
(c) It should be compatible with high throughput screening,
(d) Cost per test should be minimal, and screening
technology should be affordable to molecular diagnos-
tics laboratories.
(e) It should provide results that are easy to interpret.
DNA microarray platforms are being developed to
address these challenges. Since hybridisation of a whole
array of short oligonucleotide probes to cDNA strands
must be implemented at a stringency appropriate for all
probes, binding specificity would therefore be inadequate
to rule out mis-matches of up to 10% of the probe length
[24]. Therefore standard hybridisation cannot be used for
detection of single nucleotide polymorphisms (SNPs) on a
DNA microarray. The first microarray-based SNP detection
platform involves sequencing by hybridisation using a
panel of probes for each SNP [25] and which was first
applied to CFTR mutations by Cronin et al. [5]. While the
throughput potential of this approach is high, the level of
precision and accuracy necessary for diagnostics applica-
tion may be difficult to achieve. The second approach
involves primer extension arrays or minisequencing arrays,
in which each oligonucleotide printed on the array is
designed so that it is complementary to the sequence
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sence of the four di-deoxynucleotides (ddNTPs) where
each of the four have been labelled with a unique fluores-
cent label, hybridisation of target DNA followed by primer
extension results in incorporation of only one fluorescently
tagged ddNTP corresponding to the SNP variants present
in the template sample. Thus, using probes specific to each
of the relevant CFTR mutations, a primer extension based
DNA microarray platform has the potential to implement a
single multiplex test for all those mutations in a single
assay. The third DNA microarray platform is the Nano-
ChipR from Nanogen [7] that has already been developed
as a commercial product for screening for the ACOG/
ACMG 25 recommended mutations of the CFTR gene. The
NanoChipR technology electronically addresses each of the
probe locations, applying specific electric fields so as to
displace non-specifically bound target DNAs, thereby using
electronic stringency control to enable SNP detection. The
major challenges to be addressed with this DNA micro-
array platform will be to scale up the number of CFTR
mutations that can be screened on a single chip, and to
deliver an affordable product both in terms of the cost per
test and of the capital equipment necessary to implement
the test.5. Conclusions and recommendations
Gene expression analysis using DNA microarrays has
the potential to provide insights into the pathogenesis of
CF by identifying genes which are up- or down-regulated
as a consequence of CF. Such genes may be responsible
for a cascade effect due to the defective CFTR protein,
and may also be responsible for some of the clinical
symptoms of CF. As such, studies of changes in gene
expression across the whole genome have the potential to
identify candidate targets for the therapy of CF. DNA
microarrays also have the potential to provide a superior
alternative to existing CFTR mutation screening methods,
where all relevant CFTR mutations can be tested simulta-
neously in a single assay. However, further research is
required in the development and validation of DNA
microarray platforms to establish their suitability for such
purpose. Assuming that these platforms are capable of
simultaneously screening for mutations associated with
several genetic conditions, consideration of the ethical
implications of this approach to genetic testing will be
required [26] and a code of practice implemented to ensure
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